RESOMER R 202 S Bioresorbable Poly(D,L-lactide) Drug Delivery Grade is an amorphous ester-terminated polylactide supplied as a white to off-white granulate or powder. It is manufactured by ring-opening polymerization of D,L-lactide; the racemic stereochemistry of the lactide units prevents crystallization and yields a polymer with no melting endotherm. Inherent viscosity is measured in chloroform at 25 °C at a concentration of 0.1 g/dL using ISO 1628-1; the specification band is 0.16–0.24 dL/g. Differential scanning calorimetry per ISO 11357-2 typically gives a glass transition midpoint of 44–50 °C, and the supplier’s certificate of analysis reports lot-specific residual lactide, solvent, and metal content. The grade is intended for parenteral drug delivery where the polymer remains in the dosage form.

The S suffix denotes the ester-terminated grade in the R 202 series. The companion R 202 H carries a free carboxylic acid terminus. This difference changes early hydration and degradation kinetics more than the molecular weight difference at the same inherent viscosity band. Because a carboxylic acid end group is both more polar and catalytically active toward ester hydrolysis, R 202 H typically hydrates faster and loses molecular weight earlier in aqueous media than R 202 S; the ester-terminated grade does not eliminate acid autocatalysis once hydrolysis generates new chain-end carboxylic acid groups.

Drug delivery grade documentation normally includes residual solvent results evaluated under USP <467> or Ph. Eur. 2.4.24, bacterial endotoxins under USP <85> or Ph. Eur. 2.6.14, and biocompatibility support under ISO 10993-5 and ISO 10993-10. Because the polymer is an excipient in a final sterile product, terminal sterilization of the dosage form remains the responsibility of the applicant; the polymer itself is not supplied sterile unless specifically ordered.

How does ester terminus chemistry alter hydrolytic degradation and drug release?

In an aqueous release medium at 37 °C and pH 7.4, water enters the amorphous matrix and attacks ester linkages. The rate of early chain scission in R 202 S is limited by the low concentration of acid end groups; R 202 H, in contrast, begins with a higher density of polar acid termini that increase local water content and catalyze hydrolysis. The consequence for microsphere and implant formulations is often a lower initial release rate and lower burst from R 202 S when loaded with poorly water-soluble actives. Once degradation proceeds, the generation of lactic acid in the matrix core accelerates mass loss regardless of the original end group. Published data for this specific configuration is limited to comparative in vitro curves, so release predictions require lot-specific measurement rather than extrapolation from molecular weight alone.

For release characterization, dialysis sac methods or USP apparatus 4 flow-through cells are used, but the choice of medium influences the result. A surfactant such as 0.1% polysorbate 20 may be added to maintain sink conditions for poorly water-soluble drugs. The low molecular weight of R 202 S allows faster mass loss than grades such as R 203 S, so the release profile is often a combination of diffusion through the amorphous matrix and erosion. If the active is acidic, its presence can accelerate polymer hydrolysis, while basic drugs can neutralize carboxylic acid degradation products and retard the autocatalytic effect. These interactions require preformulation evaluations rather than reliance on polymer specification alone.

The amorphous poly(D,L-lactide) matrix absorbs more water than semicrystalline poly(L-lactide) because no crystalline phase blocks permeation. The absorbed water plasticizes the polymer and lowers the glass transition, so the dry Tg of 44–50 °C cannot be used to predict in vivo performance after hydration. For melt processing, the material must be protected from atmospheric moisture; pre-drying under vacuum at 40 °C to a residual moisture below 0.1 wt% is required before extrusion or compression molding. Exposure to relative humidity above 60% at room temperature should be avoided.

Steam sterilization is incompatible because saturated steam at 121 °C accelerates hydrolysis and deforms the low-Tg polymer. Gamma irradiation under ISO 11137 can be used but causes dose-dependent chain scission; a validated dose of 25 kGy may reduce inherent viscosity and shift release kinetics. Ethylene oxide is an alternative when residual gas limits under ISO 10993-7 can be met. Autoclaving is not recommended.

Solvent-Based Microencapsulation and Phase-Separation Limits

R 202 S is used in oil-in-water or water-in-oil-in-water emulsification for microspheres. The polymer is dissolved in dichloromethane or ethyl acetate, often at 10–20 wt% solids depending on target particle size and active solubility. A high-shear mixer such as a Silverson L5M-A operating at 5,000–10,000 rpm disperses the organic phase into an aqueous poly(vinyl alcohol) continuous phase. The low inherent viscosity of R 202 S permits concentrated solutions without exceeding the solvent-handling limits of a 4 L jacketed reactor, but the organic-phase viscosity must be measured with a Brookfield or cone-and-plate viscometer because small changes in polymer concentration alter the droplet breakup regime.

The solvent-removal step is the critical processing conflict. Dichloromethane removal is fast but yields a more porous shell if the extraction rate is uncontrolled; ethyl acetate extraction is slower and often requires a longer hardening phase. Residual solvent must meet USP <467> or ICH Q3C limits for the final formulation. With R 202 S, the ester terminus reduces early water uptake at the particle surface relative to R 202 H, which can reduce agglomeration during solvent exchange. However, if the solvent-extraction bath is held above 25 °C too long, the low Tg of the solvated polymer promotes particle coalescence.

Residual solvent analysis is commonly performed by headspace gas chromatography per Ph. Eur. 2.4.24. In microsphere formulations, dichloromethane is frequently the limiting residual because the finished dosage form must comply with ICH Q3C limits of 600 ppm for dichloromethane; ethyl acetate is less restrictive but harder to remove completely due to higher aqueous solubility. The selection of solvent therefore represents a trade-off between processability and regulatory compliance.

When substituting R 202 S for R 202 H in a microsphere formulation, a direct mass-for-mass replacement is not reliably equivalent. The change in end-group polarity shifts initial burst release by altering drug-polymer phase separation. The organic-phase solution viscosity should be matched by adjusting polymer concentration or solvent blend; otherwise the mean particle size may shift because droplet breakage in the high-shear mixer depends on dispersed-phase viscosity. A preformulation comparison using laser diffraction per ISO 13320-1 is recommended to track particle-size distribution.

The inherent viscosity specification is not a direct process control for emulsification. The organic-phase viscosity of a 15 wt% R 202 S solution in dichloromethane at 25 °C is typically below 100 mPa·s, but the addition of a hydrophobic active can reduce or increase viscosity depending on drug-polymer interactions. Because droplet size in turbulent emulsification scales with dispersed-phase viscosity, a change from 0.16 dL/g to 0.24 dL/g within the allowed specification can shift the mean microsphere diameter by several micrometers at constant mixer speed. This is a batch-to-batch variable that must be controlled by measuring solution viscosity before emulsification.

Melt extrusion of R 202 S is feasible but not the primary route for drug delivery because the low molecular weight produces a low-viscosity melt and a narrow processing temperature window. On a co-rotating twin-screw extruder with an L/D ratio of 25:1, conveying at barrel temperatures of 110–130 °C is possible for the neat polymer, but heat generated in kneading blocks can regenerate lactide and reduce molecular weight. Screw configurations should use low-shear conveying elements after the melting section. When an active pharmaceutical ingredient is compounded, the barrel temperature must remain below the degradation onset of the active, often 90–110 °C, which approaches the lower limit for melt conveying; published data for this specific configuration is limited.

For continuous melt processing, the feed throat should be inerted with nitrogen to prevent oxidative yellowing, and the melt temperature should be monitored with an infrared probe at the die. The low molecular weight leads to die drool if the die is held above 140 °C for extended periods. These observations are common to low-molecular-weight polylactides and are not unique to R 202 S, but they define the practical window for compounding with heat-sensitive drugs.

R 202 S can also be dissolved in water-miscible aprotic solvents such as N-methyl-2-pyrrolidone or dimethyl sulfoxide for in-situ forming depot injections. The solution is injected into an aqueous environment, and the polymer precipitates as the solvent exchanges with water. The resulting depot is amorphous and can release drug over weeks to months. The ester terminus slows the initial acidic surface layer compared with an acid-terminated polymer, which may benefit acid-sensitive actives. The injectable solution must remain within the force limit of a 21-gauge needle; this usually restricts the polymer concentration to 10–20 wt%. Solvent selection must consider the drug’s partition coefficient, because rapid solvent extraction can leave a porous depot that releases active by diffusion rather than by controlled erosion.

Compared with poly(D,L-lactide-co-glycolide) of similar inherent viscosity, R 202 S lacks glycolic acid repeat units. Glycolic acid units increase hydrolysis rate; therefore R 202 S degrades more slowly than PLGA 50:50 and generates a less rapid initial acid microclimate. The absence of glycolide also changes degradation-product pH behavior; PLGA 50:50 produces glycolic acid, which is a stronger acid than lactic acid. The slower acid generation from R 202 S makes it a candidate when the active is a protein or peptide with acid-labile stability; however, even poly(D,L-lactide) eventually produces lactic acid and can lower pH in confined matrices. Buffered release media and basic additives such as magnesium hydroxide have been used to limit acidification, but such additives may alter polymer degradation and must be tested under the final dosage form design.

Compared with poly(L-lactide), R 202 S is amorphous, has a lower Tg, dissolves more readily in dichloromethane and ethyl acetate, and lacks mechanical strength sufficient for load-bearing orthopedic screws. Those properties position R 202 S for microspheres, implants, and depot formulations rather than for structural fixation. The absence of crystallinity eliminates the need for annealing performed with semicrystalline PLLA.

The R 202 series specification contrast

The table compares the ester-terminated R 202 S with adjacent RESOMER grades that are commonly evaluated in controlled-release projects. The values are supplier specification ranges, not release-rate predictors.

Molecular weight distribution is determined by gel permeation chromatography in tetrahydrofuran or chloroform against polystyrene standards; results are therefore relative rather than absolute. The conversion from polystyrene-equivalent molar mass to poly(D,L-lactide) absolute molar mass requires universal calibration or multi-angle light scattering. Without that correction, molecular weight comparisons between grades and suppliers can be misleading, especially for low-molecular-weight grades such as R 202 S.

For sterile drug delivery applications, the polymer is commonly dissolved, sterile-filtered, and then processed aseptically. The low molecular weight of R 202 S allows filtration of organic-phase solutions through 0.2 µm polytetrafluoroethylene filters, but the filter load and throughput depend on solution viscosity and particulate level. Sterile filtration of the final microsphere suspension is generally not possible; therefore, aseptic manufacturing or terminal sterilization of the drug product is required. The polymer itself should be handled in an ISO class 8 or better environment if the final product is intended for parenteral use.

When R 202 S is processed below its glass transition

Because the glass transition is near 44–50 °C, R 202 S is stiff and brittle at room temperature but softens at body temperature. This creates a processing boundary in milling and cryogenic micronization. At room temperature, the polymer may deform or block during jet milling; wet milling or cryogenic milling with liquid nitrogen is used to produce fine powders for solid dispersions. The low Tg also limits drying after aqueous processing; vacuum drying above 40 °C risks particle fusion. When the polymer is used as a coating or film, plasticizers may be required to lower the glass transition further, but plasticizer selection must avoid basic amines that accelerate ester cleavage.

The polymer is soluble in chlorinated solvents such as dichloromethane and chloroform, and in polar aprotic solvents such as acetone and ethyl acetate; it is insoluble in water, methanol, and hexane. Solubility in ethyl acetate decreases if the polymer is stored under humid conditions and partially hydrolyzes, so storage under sealed, dry conditions at −20 °C is recommended. Incompatible additives include strong bases, amines, and organometallic compounds that catalyze transesterification or chain scission. Oxidation is not the primary degradation route, but long-term exposure to heat and air can yellow the material.

Lot-to-lot variation within the inherent viscosity band can shift release kinetics. In a microsphere batch, a change from 0.18 dL/g to 0.23 dL/g may increase the organic-phase viscosity enough to change the particle size at a fixed mixer speed. Manufacturers should compare the certificate of analysis, residual lactide, and glass transition midpoint when qualifying a new lot. If the material is sourced as a drug delivery grade, the supplier documentation should include the biological evaluation file, residual solvent data, and the method used to determine molecular weight distribution.